Thermography Is Not a Feasible Method for Breast Cancer Screening by Boris Brkljačić et al.
Coll. Antropol. 37 (2013) 2: 589–593
Reply and comment
Thermography Is Not a Feasible Method for
Breast Cancer Screening
Boris Brklja~i}1, Damir Mileti}2 and Francesco Sardanelli3
1 University of Zagreb, School of Medicine, Dubrava University Hospital, Department of Diagnostic and Interventional Radiology,
Zagreb Croatia; and President of Croatian Society of Ultrasound in Medicine and Biology, Zagreb Croatia
2 University of Rijeka, School of Medicine, Rijeka University Hospital Center, Department of Radiology, Rijeka, Croatia;
and President of Croatian Society of Radiology, Zagreb Croatia
3 University of Milano, IRCCS Policlinico San Donato, Department of Biomedical Sciences for Health, Unit of Radiology, Milano
Italy; and President of European Society of Breast Imaging, Vienna, Austria
A B S T R A C T
Breast cancer is a common malignancy causing high mortality in women especially in developed countries. Due to the
contribution of mammographic screening and improvements in therapy, the mortality rate from breast cancer has de-
creased considerably. An imaging-based early detection of breast cancer improves the treatment outcome. Mammography
is generally established not only as diagnostic but also as screening tool, while breast ultrasound plays a major role in
the diagnostic setting in distinguishing solid lesions from cysts and in guiding tissue sampling. Several indications are
established for contrast-enhanced magnetic resonance imaging. Thermography was not validated as a screening tool
and the only study performed long ago for evaluating this technology in the screening setting demonstrated very poor re-
sults. The conclusion that thermography might be feasible for screening cannot be derived from studies with small sam-
ple size, unclear selection of patients, and in which mammography and thermography were not blindly compared as
screening modalities. Thermography can not be used to aspirate, biopsy or localize lesions preoperatively since no me-
thod so far was described to accurately transpose the thermographic location of the lesion to the mammogram or ultra-
sound and to surgical specimen. Thermography cannot be proclaimed as a screening method, without any evidence
whatsoever.
Introduction
Breast cancer is a common malignancy causing high
mortality especially in developed countries. Due to the
contribution of mammographic screening and improve-
ments in therapy, between 1990 and 2007 the mortality
rate from breast cancer in the United States has de-
creased by 31%1,2 and a similar trend was observed in
Sweden where long-term (29-year) effects of mammo-
graphic screening could be evaluated3. In Croatia, breast
cancer causes the death of more than 900 women annu-
ally and its incidence is steadily increasing over the
years; since 2006, women from 50 to 69 are invited bian-
nually in the context of a national program for mammo-
graphic screening4.
An imaging-based early detection of breast cancer im-
proves the treatment outcome. In fact, breast conserving
surgery is currently established as a standard of care of
small breast cancers, combined with sentinel node biopsy
and followed by radiation therapy, systemic chemother-
apy, and/or hormonal/targeted therapy5. Radiologic-pa-
thologic correlation is crucial for the proper management
of patients6.
Imaging Methods Used for the Diagnosis
of the Diseases of the Breast
While mammography is generally established not
only as diagnostic but also as screening tool, breast ultra-
sound plays a major role in the diagnostic setting in dis-
tinguishing solid lesions from cysts and especially in
guiding tissue sampling using fine needle aspiration cy-
tology and, increasingly in the last decades, core needle
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biopsy7. Mammography has well-known limitations in
sensitivity in young women and dense breasts and breast
ultrasound has advantages in these conditions as shown
not only in the diagnostic8 but also in the screening
setting9,10. Digital mammography11, thomosyntesis12,13,
and contrast-enhanced mammography14 are recent ad-
vances.
Contrast-enhanced magnetic resonance imaging (MRI)
has entered this field in the last two decades. The diagno-
sis is based on morphology and the functional parame-
ters reflecting pathologic neovascularization by various
patterns of lesion enhancement, which can be analyzed
by generating dynamic (kinetic) curves for targeted re-
gion-of-interests15. Several indications are established
for breast MRI, the most important among them being
screening of high-risk women, search for carcinoma un-
known primary, prediction and evaluation of the effect of
neoadjuvant chemotherapy, suspected local recurrence16–18.
A debate is still open on the use of breast MRI in the pre-
operative setting19–21.
Imaging features of benign and malignant breast le-
sions often overlap and imaging-guided needle biopsies
are needed to define the diagnosis. Whenever possible,
ultrasound-guidance is used while mammographic ste-
reotactic and MRI guidance are used for findings such as
microcalcifications/architectural distortions and con-
trast-enhancing lesions not detectable at mammography
or ultrasound, respectively. In the case of malignancy,
pathologic diagnosis of cancer subtype, grade, estrogen
and progesterone receptor status, and human epidermal
growth factor receptor 2 (HER2) expression, which are
important and robust prognostic biomarkers22, are ob-
tained by means of core-biopsy or vacuum-assisted bi-
opsy and confirmed/completed at final pathology of sur-
gical specimen.
Breast Thermography
Breast thermography, also known as infrared imaging
of the breast is a noninvasive method that measures tem-
peratures and temperature differences across the skin
surface using infrared cameras. Results are displayed as
maps of different colors. The rationale is that breast can-
cers have higher temperatures compared to normal breast
tissue due to neoangiogenesis and increased metabolic
activity. It was firstly performed in 1956, and studied
forty years ago. In 1977 Feig et al. reported results of a
very large study comparing mammographic and thermo-
graphic breast cancer screening in 16,000 women: sensi-
tivity of thermography was 39%, specificity 82%. Authors
concluded that thermography was not a viable screening
tool23.
Recent studies have examined a newer infrared tech-
nology, the so-called digital infrared thermal imaging
(DITI). Arora at el imaged with DITI 92 women with 94
suspicious lesions detected by mammography or ultra-
sound: sensitivity was 94% but specificity 28%24. Wishart
et al. examined with DITI (combined with a new soft-
ware) 100 women with suspicious lesions undergoing
core needle biopsy and found for DITI a sensitivity of
78% and a specificity of 89%25. Kontos et al. studied with
DITI 63 symptomatic women who underwent surgical
excision or core biopsy. Thermography had a sensitivity
of 25% and a positive predictive value of 24%. Authors
conclude that thermography is not indicated for the pri-
mary evaluation of symptomatic patients, nor should it
be used for breast cancer screening26. All these recent
studies compared the performance of DITI to mammog-
raphy in a population of symptomatic patients with sus-
picious or highly suspicious lesions. None of these studies
tested thermography in a screening setting.
The Society of breast imaging (SBI), the leading U.S.
scientific and professional society in the field, has issued
in 2011 a position statement regarding breast thermo-
graphy27: SBI does not support the use of thermography
or infrared imaging as either a screening tool in the de-
tection of breast cancer or as an adjunctive diagnostic
tool. According to this view, there are no studies support-
ing the use of thermography alone or as an adjunct to
mammography that show clear benefits of the technique
and it is unclear how the abnormal areas detected by
thermography were aspirated or biopsied; moreover, no
method was described to accurately transpose the ther-
mographic location of the lesion to the mammogram and
then to the actual location in the breast27.
The Food and Drug Administration (FDA), which is
the official agency of the U.S. Department of Health and
Human Services, has issued a strong statement in June
201128 expressing concern regarding facilities, mobile
units, and websites promoting the use of thermography
as a stand-alone tool for screening and diagnosing breast
cancer, claiming that it is substitute for mammography
or superior to mammography, that thermography can de-
tect precancerous abnormalities and diagnose breast
cancer long before mammography and that compressing
breast during mammography will cause spread of cancer.
FDA is concerned that women will believe these mislead-
ing claims about thermography and not receive needed
mammograms. FDA has alerted public, including women
and health care providers, that thermography is not a re-
placement for screening mammography and should not
be used by itself to diagnose breast cancer. FDA is not
aware of any valid scientific data to show that thermo-
graphy devices, when used on their own, are an effective
screening tool for any medical condition, including early
detection of breast cancer or other breast diseases. Pub-
lic health agencies and national medical and professional
societies agree with FDA that mammography is still the
most effective method of detecting breast cancer in its
earliest, most treatable stages. These organizations in-
clude the American Cancer Society, the American College
of Radiology, the Centers for Disease Control and Pre-
vention, the National Cancer Institute, and the SBI28.
The Croatian Society of Radiology and Croatian Soci-
ety of Senology have issued similar public statements in
February 201329,30, as a reflection of public promotion in
Croatia of thermography as a stand-alone tool for screen-










ing and diagnosing breast cancer and precancerous ab-
normalities.
Reply to the Paper Claiming that Breast
Thermography Might Be a Feasible
Method for Screening of Breast Cancer
In this context, in the current issue of Collegium
Antropologicum a paper is published by Kolari} et al., en-
titled »Thermography – A feasible method for screening
of breast cancer?«31. Authors claim that thermography
had sensitivity of 100% and specificity of 79% and that
sensitivity of thermography is superior to mammogra-
phy. Authors conclude that their »results indicate that it
would be prudent to use thermography as a primary
screening method in detection of breast carcinoma«. This
conclusion is not only contradictory to the aforemen-
tioned position statements but is also not supported by
the data presented by the authors.
The analysis of the paper by Kolari} et al. is difficult
because crucial information is often missing, incomplete,
or contradictory. The main heavy problems and limita-
tions of this study can be summarized as follows.
First, a too small group of patients was studied, con-
sisting of only 26 women. With such a sample size, any
statistical evaluation cannot allow for reliable conclu-
sions. According to the authors, of 27 ductal carcinoma in
situ (DCIS) (N=12) or invasive cancers (N=15, as de-
clared in Table 2, but they are only 13 in Table 1), mam-
mography detected 85% (we assume 23/27) and ther-
mography 100% (27/27). However, had the authors really
calculated 95% interval confidence (as they declare in the
text), they would have found 71%–98% for mammogra-
phy and 87%–100% for thermography, with 11% of over-
lapping. With only 4 (or also 5) different results, also the
nonparametric McNemar test cannot provide any signifi-
cant p value. Thus, no superior sensitivity of thermogra-
phy versus mammography, no potential use of thermo-
graphy for an earlier detection of breast cancer can be
claimed on the basis of these results. By the way, why are
no results provided for the breast ultrasound?
Second, selection of the patients is unclear. We only
know that this is a (really consecutive?) series of 26 wo-
men scheduled for breast surgery. Were they symptom-
atic or asymptomatic? Do they come from screening or
diagnostic mammography or ultrasound? Which was the
size of the index lesions? In fact, it is clear that if also
only part of them were not asymptomatic, independently
from the small sample size, no inference about screening
could be derived. Of note, the author present a series of
26 women scheduled for surgery but 6 of them (23%) had
no cancers, thus 5 of 20 women with malignant disease
had synchronous bilateral cancers (25%), a too high rate
which generates some doubt about a possible selection
bias and nonconsecutiveness of the series.
Third, while the proclaimed aim of the study by
Kolari} et al. was »to evaluate thermography as possible
method for early detection of breast carcinoma, and to
compare its sensitivity and specificity to that of mam-
mography«, this was not performed at all since mammog-
raphy and thermography were not compared as screen-
ing modalities, nor were they compared in a fashion
blinded to the results of mammography and ultrasound,
preventing from any possibility to analyze results from
thermography alone, but only from thermography as an
adjunct to mammography and/or ultrasound.
Fourth, no explanation was given on how lesions only
detected at thermography were aspirated and localized
for surgical excision. No method so far was described to
accurately transpose the thermographic location of the
lesion to the mammogram or ultrasound and to surgical
specimen. Authors do not mention any method of preop-
erative image-guided tumor localization and it is impos-
sible to understand how the changes observed on ther-
mography could be correlated to the lesions found in the
resection specimens. Authors claim that only thermo-
graphy was able to diagnose several DCIS. And if DCIS
was observed only on thermography, how can the invisi-
ble DCIS be removed when thermography cannot local-
ize it within the breast since is well known that ther-
mographic location of the lesion cannot be accurately
transposed to the surgical specimen? The current prac-
tice is to perform preoperative localization under ima-
ging guidance of impalpable lesions, including DCIS in
patients undergoing conservative surgery. How did the
authors perform this, or have they subjected patients
with DCIS to mastectomy? If yes, is this justifiable?
Fifth, there is a complete lack of information about
type of surgery performed (conservative surgery versus
mastectomy). Sixth, as mentioned above, 6 of 26 patients
(23%) had nonmalignant findings histopathology. We
should think that this was done due to the presence of a
non better specified atypia/proliferation at cytology, but
this really seems a too high rate of surgical biopsy of
non-malignant findings. Seventh, an unusual categoriza-
tion of histopatological results was used, without provid-
ing information about subtype and grade of cancer, eval-
uation of intraductal component associated with invasive
cancers, receptor status, HER2neu expression, and so
on. By the way, this paper being a small radiology-cytho-
logy-pathology-surgery correlation study, we should note
that neither surgeons nor pathologists are among the
co-authors.
Eight, it is quite unexpected that a number of DCIS
(we do not know their grade) were only detectable on
thermography. In fact, being DCIS noninvasive lesions
with relatively low neoangiogenesis32, how can we ex-
plain that a method based on differences in (skin) tem-
perature is so sensitive for non-invasive lesions? A poten-
tial higher sensitivity should be somehow thought for
invasive highly neoangiogenetic cancers, not for DCIS.
However, the authors do not discuss this issue.
Conclusion
Breast cancer screening is very important for women
and for the public all over the world. Mammography was










studied and validated as a screening modality in hun-
dreds of thousands of patients in organized screening
programs performed for decades in the developed coun-
tries with the best health care systems and meticulous
quality control evaluation. We are aware of the scientific
discussion about the relative contribution of mammo-
graphic screening to the decrease of breast cancer mor-
tality as well as about limitations of screening mammog-
raphy and the debatable rate of »overdiagnosis« and
negative effects of mammographic screening33–37. How-
ever, unlike mammography, thermography was never
used nor validated as a screening tool and the only study
performed long time ago demonstrated very poor re-
sults23.
To summarize, the study by Kolari} et al. does not add
any valid information to support the use of the thermo-
graphy as a primary screening of breast cancer. Unfortu-
nately statements like those contained in this study are
misleading for the public, and may raise false hopes and
confuse many women who are exposed to the aggressive
advertising of unproven »advantages« of thermography.
Thermography cannot be proclaimed as a screening me-
thod, without any evidence whatsoever.
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TERMOGRAFIJA NIJE PRIKLADNA METODA ZA PROBIR KARCINOMA DOJKE
S A @ E T A K
Karcinom dojke je ~esta bolest koje uzrokuje visoku smrtnost `ena, osobito u razvijenim zemljama. Mamografski
probir (skrining) i pobolj{anja u lije~enju doprinijeli su zna~ajnom smanjenju smrtnosti. Otkrivanje karcinoma dojke u
ranom stadiju temeljeno na slikovnim metodama pobolj{ava ishod lije~enja. Mamografija je op}enito etablirana ne samo
kao dijagnosti~ka metoda nego kao i metoda probira. Ultrazvuk ima veliki dijagnosti~ki zna~aj u razlikovanju solidnih
lezija dojke i cista, a osobito pri nadzoru punkcija i biopsija. Magnetska rezonancija dojki uz intravensku primjenu
kontrasta ima nekoliko utvr|enih indikacija. Termografija nije validirana kao metoda probira; jedino davno provedeno
istra`ivanje u kojem je ova tehnologija istra`ivana u probiru pokazalo je vrlo lo{e rezultate. Zaklju~ak da bi termografija
mogla biti prikladna za probir ne mo`e se izvesti na temelju studija provedenih na malom uzorku, s nejasnom selek-
cijom bolesnica, u kojima mamografija i termografija nisu uspore|ene kao metode probira. Termografija ne omogu}uje
aspiraciju, biopsiju niti preoperacijsku lokalizaciju lezija jer do sada nije opisan na~in kako bi se termografska lokacija
lezija to~no prenijela na mamogram, ultrazvuk ili kirur{ki uzorak. Termografija se ne mo`e progla{avati metodom
probira (skrininga) bez ikakvih valjanih dokaza.
B. Brklja~i} et al.: Thermography Is Not Feasible for Breast Cancer Screening, Coll. Antropol. 37 (2013) 2: 589–593
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